Development of EFTX-001 to Target KRAS Mutations in Cancer
NCBiotech Grants & Loans
See the full listing of all NCBiotech grants and loans awarded since July 2012.
Organization
UNC - Chapel Hill
Award Date
Award Amount
100,000
Program Name
Translational Research Grant
Program Category
Research and Equipment Support
Principal Investigator
Chad Pecot
Fiscal Year
2019
Region
Research Triangle
Project Description:
One of the most well-identified cancer genes is called KRAS. Despite being discovered more than 40 years ago, KRAS has been deemed "undruggable" and could not be targeted for development of cancer therapetucs . Using a technique called RNA interference, we have developed EFTX-001, which is a drug that targets KRAS. The research to be conducted will evaluate the efficacy and possible toxicity of EFTX-001 to treat KRAS-driven cancers.